106 results on '"Wei, J. C.‐C."'
Search Results
2. AB0868 HOW DO EARLY DISEASE ACTIVITY AND EARLY CLINICAL RESPONSE ASSOCIATE WITH LONG-TERM OUTCOMES WITH IXEKIZUMAB IN RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS?
3. Association of sepsis with risk for osteoporosis: a population-based cohort study
4. POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
5. POS1119 ARE WE TREATING-TO-TARGET IN SPONDYLOARTHRITIS (SPA)? A ONE-YEAR ANALYSIS FROM THE ASIA PACIFIC LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (APLAR) SPA REGISTRY
6. OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
7. POS0302 TREAT-TO-TARGET IN SPONDYLOARTHRITIS (SPA): ARE THERE SEX-RELATED DIFFERENTIAL RESPONSES?
8. 1319 INTERACTION BETWEEN DISTINCT MULTIMORBIDITY PATTERNS AND DISABILITY AND ITS ASSOCIATION WITH FUTURE MORTALITY AMONG OLDER ADULTS
9. 1266 ASSOCIATION OF MULTIMORBIDITY PATTERNS AND INCIDENT DEPRESSION AMONG OLDER ADULTS IN TAIWAN: ROLE OF SOCIAL PARTICIPATION
10. Comment on short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes
11. POS0931 EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL
12. AB0761 Are we treating-to-target in spondyloarthritis (SpA)? A cross sectional analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
13. POS0712 YEAR-4 OBSERVATIONAL FOLLOW-UP OF BELIMUMAB SAFETY (MORTALITY AND MALIGNANCIES) IN PATIENTS WITH SLE WHO COMPLETED A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED SAFETY STUDY
14. Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients: A population‐based cohort study
15. Risk of stroke with antivenom usage after venomous snakebite in Taiwan: a population-based cohort study
16. Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis
17. POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL
18. AB0288 SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: YEAR 2 FOLLOW-UP OF A LARGE PHASE 4, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
19. Risk of stroke with antivenom usage after venomous snakebite in Taiwan: a population-based cohort study.
20. Association of sepsis with risk for osteoporosis: a population-based cohort study
21. Traditional Chinese medicine use may reduce medical utility in patients with asthma: a nationwide population-based retrospective cohort study
22. THU0396 IMPACT OF IXEKIZUMAB ON WORK PRODUCTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS FROM THE COAST-V AND COAST-W TRIALS AT 52 WEEKS
23. OP0107 ETANERCEPT WITHDRAWAL AND RE-TREATMENT IN PATIENTS WITH INACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AT 24 WEEKS: RESULTS OF RE-EMBARK, AN OPEN-LABEL, PHASE IV TRIAL
24. OP0225 TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE
25. Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis
26. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese
27. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity
28. Scleroderma and failed response to alefacept
29. Study of undifferentiated spondyloarthropathy among first-degree relatives of ankylosing spondylitis probands
30. Traditional Chinese medicine use may reduce medical utility in patients with asthma: a nationwide population-based retrospective cohort study.
31. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients
32. Association of gout medications and risk of cataract: a population-based case–control study
33. Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sjögren syndrome
34. Plasma pyridoxal 5′-phosphate is not correlated with hemoglobin during pyridoxine supplementation in patients with rheumatoid arthritis
35. Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study
36. Syncope caused by complete heart block and ventricular arrhythmia as early manifestation of systemic lupus erythematosus in a pregnant patient: a case report
37. ARE WE TREATING-TO-TARGET IN SPONDYLOARTHRITIS (SPA)? A ONE-YEAR ANALYSIS FROM THE ASIA PACIFIC LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (APLAR) SPA REGISTRY.
38. TREAT-TO-TARGET IN SPONDYLOARTHRITIS (SPA): ARE THERE SEX-RELATED DIFFERENTIAL RESPONSES?
39. SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).
40. Response to: Risk of hemorrhagic stroke after venomous snakebite: correspondence.
41. Response to: Traditional Chinese medicine use may reduce medical utility in patients with asthma: correspondence.
42. AB0742 Intravenous Loading and Subcutaneous Maintenance with Secukinumab Provides Sustained Improvement in Multiple Measures of Disease Activity in Subjects with Active Ankylosing Spondylitis: 52-Week Data From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Measure 1 Study
43. OP0168 Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Data from Measure 2, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
44. A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS.
45. SAT0372 Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 48-Week Treatment Data: Table 1.
46. Regarding: Increased fracture risk after discontinuation of anti‐osteoporosis medications among hip fracture patients.
47. Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis
48. Plasma pyridoxal 5′-phosphate is not correlated with hemoglobin during pyridoxine supplementation in patients with rheumatoid arthritis
49. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis
50. Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.